A randomized, open-labelled non-drug interventional, cross-over, dry powder inhaler device preference study to compare “ease of use” of ELLIPTA (TM) inhaler with BREEZHALER (TM) inhaler in inhalation-device naïve Japanese volunteers aged 40 years or older

Trial description: This will be a single-centre, randomized, open-label, 2-period crossover study using another inhaler as controls without any pharmacological intervention.This study is designed to demonstrate ELLIPTA inhaler is easy to use in Japanese adult subjects aged 40 years or older with no history of regular use of a dry powder inhaler . The study will enroll subjects aged 40–64 years and >= 65 years in a ratio of 1:2. The male and female ratio will be 1:1. Each subject will be randomized to one of the two sequences from Sequence 1 to Sequence 2. Subjects will use two different inhalers ELLIPTA inhaler and BREEZHALER inhaler one after another in order designated by the allocated sequence. All two inhalers will be assessed on the same day by the same rater.ELLIPTA inhaler and BREEZHALER inhaler used in this study are not going to contain the active drugs.Empty capsules are going to be prepared for handling of BREEZHALER inhaler. This study will assess the technique in the inhaler handling until just before inhalation as subjects are not going to inhale.ELLIPTA inhaler is a trademark of GlaxoSmithKline pharmaceuticals.BREEZHALER is a trademark of Novartis AG.